CDK4/6i reverses MEIS2 inhibition of CRL4CRBN and promotes BCMA loss to enhance IMiD/CELMoD therapy in multiple myeloma

Blood Neoplasia · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles